Assay News and Research

RSS

Origene Technologies' acquisition of Marligen Biosciences reinforces its leading position in the bio-medical research industry

OriGene Technologies, Inc. today announced the acquisition of Marligen Biosciences, Inc., a provider of cutting-edge multiplex assays for the Luminex xMAP(R) platform for protein and gene expression profiling assays and testing services, and DNA and RNA purification kits.

20 Oct 2009

Chrysanthemum indicum extract holds promise for treating human cancer

A series of studies have demonstrated that Chrysanthemum indicum possesses antimicrobial, antiinflammatory, immunomodulatory, and neuroprotective effects. Recently, much attention has been devoted to the anticancer activity of Chrysanthemum indicum, especially in hepatocellular carcinoma (HCC). However, its anticancer mechanism of action is still not clear and needs further investigation.

19 Oct 2009

TheraDoc commences beta testing of new computerized patient surveillance tool

TheraDoc®, the leading provider of clinical decision support technology in healthcare, today announced that it has started beta testing of a new computerized patient surveillance tool that will help hospitals monitor and manage screening programs for multidrug-resistant organisms (MDROs), such as methicillin-resistant Staphylococcus aureus, or MRSA, which every year kills more people in the United States than AIDS.

19 Oct 2009

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with “Epigenetics & Chromatin Modification” at the Society for Neuroscience’s, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.

15 Oct 2009

PIKAMAB obtains U.S. patent rights to develop theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.

15 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

DNA authentication technology to distinguish between in-vivo and in-vitro DNA

Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced that company researchers today presented its DNA authentication technology, a novel assay to distinguish between in-vivo (real) and in-vitro (fake) DNA, at the 20th International Symposium on Human Identification in Las Vegas, Nevada.

15 Oct 2009

Affymetrix unveils Axiom Genotyping Solution

Affymetrix, Inc. (Nasdaq:AFFX) today announced the launch of the Axiom Genotyping Solution, its next-generation array technology designed to match the significant rise in genetic content generated by government and privately funded sequencing projects.

From Beckman Coulter Life Sciences - Automation and Genomics 15 Oct 2009

SwitchGear Genomics introduces high-throughput research tools for profiling biological pathway regulation

SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the availability of the first cost-effective, high-throughput research tools for screening transcriptional activation and repression in a number of key biological pathways.

14 Oct 2009

Researchers develop magneto-nano sensor chip to detect cancer

Searching for biomarkers that can warn of diseases such as cancer while they are still in their earliest stage is likely to become far easier thanks to an innovative biosensor chip developed by Stanford University researchers.

14 Oct 2009

NIBIB awards $1M grant to develop a rapid test for sepsis-related pathogens

Smiths Detection today announces the award of a $1m, two-year grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) to develop a rapid test for eight micro-organisms that commonly cause burn/wound infections leading to septicemia (blood-poisoning).

14 Oct 2009

Researchers discover compounds that show promise as novel treatments for AIDS

While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.

14 Oct 2009

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Orion Genomics today announced that it has entered into a multi-year collaboration and license agreement with the molecular diagnostics unit of Novartis Pharma AG. Under the collaboration, the parties seek to discover novel epigenetic biomarkers, and both parties have rights to independently develop and commercialize diagnostic products in their respective fields.

12 Oct 2009

Women with increased levels of M-llerian inhibiting substance are at risk of breast cancer

Women with increased levels of M-llerian inhibiting substance (MIS), best known for regulating in utero sexual differentiation in boys, may be at a greater risk for breast cancer, according to a new study published online October 9 in the Journal of the National Cancer Institute.

12 Oct 2009

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

TargetEx to be the coordinator for CancerGrid consortium

TargetEx llc, Budapest announced today that the Research Directorate General of the Commission of the European Communities approved the transfer of the coordinator responsibilities of the European Cancer Research Consortium (CancerGrid) to TargetEx.

9 Oct 2009

Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

Applied NeuroSolutions, Inc.(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples.

9 Oct 2009

BioFocus to use DiscoveRx's GPCR screening assay and associated cell lines

DiscoveRx Corp. and BioFocus® announced today that they have signed a co-marketing agreement that allows BioFocus to perform screening on behalf of BioFocus’ customers using DiscoveRx PathHunter™ ß-Arrestin GPCR screening assay, HitHunter™ cAMP assays and associated cell lines.

9 Oct 2009

Dominion Diagnostics enhances laboratory testing procedure for chronic opioid pharmacotherapy

Only a short time after introducing its newly developed and validated tapentadol assay, Dominion Diagnostics (Dominion) is pleased to announce an important enhancement to another clinical laboratory test.

8 Oct 2009

Assay News and Research

Origene Technologies' acquisition of Marligen Biosciences reinforces its leading position in the bio-medical research industry

Chrysanthemum indicum extract holds promise for treating human cancer

TheraDoc commences beta testing of new computerized patient surveillance tool

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

PIKAMAB obtains U.S. patent rights to develop theragnostic product

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

DNA authentication technology to distinguish between in-vivo and in-vitro DNA

Affymetrix unveils Axiom Genotyping Solution

SwitchGear Genomics introduces high-throughput research tools for profiling biological pathway regulation

Researchers develop magneto-nano sensor chip to detect cancer

NIBIB awards $1M grant to develop a rapid test for sepsis-related pathogens

Researchers discover compounds that show promise as novel treatments for AIDS

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Women with increased levels of M-llerian inhibiting substance are at risk of breast cancer

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

TargetEx to be the coordinator for CancerGrid consortium

Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

BioFocus to use DiscoveRx's GPCR screening assay and associated cell lines

Dominion Diagnostics enhances laboratory testing procedure for chronic opioid pharmacotherapy

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News